Compare Consolidated Edison, Inc. (ED) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Sana Biotechnology Inc — how do they compare? Consolidated Edison, Inc. trades at $105.92 (market cap $39.20B), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: Consolidated Edison, Inc. is far larger — about 46.9× Sana Biotechnology Inc's market cap, and Consolidated Edison, Inc. pays a 3.31% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and Sana Biotechnology Inc for 23 Days on average.
| ED | SANA | |
|---|---|---|
Market Cap | $39.20B | $836.71M |
Volume | 2,142,900 | 4,507,444 |
Sector | Utilities | Health |
52-Week High | $115.46 | $5.92 |
52-Week Low | $95.37 | $2.68 |
Typical Hold Time | 75 Days | 23 Days |
Enterprise Value | $66.05B | $749.96M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $105.94, up 1.23% today, near the consensus price target of $106.33. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages, while fundamentals reflect steady utility performance with 2025 revenue of $16.92B and net income of $2.02B. Recent news highlights its $24.8B economic impact in New York and upcoming investor webcast, reinforcing its stable dividend aristocrat status.
ED offers a defensive investment with a reliable dividend and moderate growth, but faces risks from high debt levels and interest expenses. Analyst sentiment is cautious with 62.96% hold ratings, suggesting limited near-term upside despite solid cash flow generation. The stock's appeal lies in its income stability amid economic uncertainty, though execution on capital expenditures remains key to sustaining growth.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
